Blog - Page 280 of 5680 - QualityStocks

ThursdayAug 07, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…

WednesdayAug 06, 2025 12:45 pm

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Launches AI-Powered Touchless Neural Control Project for Military Use

Wearable Devices (NASDAQ: WLDS, WLDSW), a developer of AI-powered touchless sensing wearables, announced the launch of a military-focused project to advance human-machine interface (HMI) technology. The initiative aims to deliver a neural control system enabling soldiers to operate tactical systems through intuitive gestures without physical contact. Powered by the company’s proprietary neural interface and AI-driven sensors, the technology is designed to enhance battlefield efficiency and safety. This move reinforces Wearable Devices’ leadership in neural input innovation and expands its reach into the defense sector. To view the full press release, visit https://ibn.fm/8EJBq About Wearable Devices Ltd. Wearable Devices Ltd. (NASDAQ:…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 12:10 pm

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial

Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug (“IND”) application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (“GBM”) at first progression. The study will evaluate safety, tolerability and preliminary efficacy in recurrent GBM, a highly aggressive brain cancer with limited treatment options. STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, and its effect is enhanced by spironolactone, which induces NER deficiency in tumor cells. The therapy has received…

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:10 am

Bollinger Innovations Inc. (NASDAQ: BINI) Drives Commercial EV Leadership with Bold Rebrand, Market Clarity

Mullen Automotive recently brought all of its EV products and brands together under one strong and unified identity — Bollinger Innovations. The pivot to one commercial EV brand comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets. The company’s new identity is also trading under new Nasdaq stock symbol NASDAQ: BINI. The company’s move under one brand clarifies market positioning, creating cohesion across product lines ready to service the commercial vehicle industry. Bollinger Innovations (NASDAQ: BINI), formerly known as Mullen Automotive, has completed a major corporate transformation, officially rebranding and switching its NASDAQ ticker from MULN to…

WednesdayAug 06, 2025 10:00 am

QualityStocksNewsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Offers $7,500 Price Cut on Mullen ONE and THREE EVs Ahead of Incentive Deadline

Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced $7,500 in additional price adjustments for commercial customers purchasing existing inventory of its Mullen ONE and Mullen THREE EVs. With MSRPs now set at $27,000 and $61,000 respectively, the incentive—combined with a $7,500 Inflation Reduction Act credit for deliveries before September 30—positions both models as high-value options in the Class 1 and Class 3 commercial EV segments. Formerly known as Mullen Automotive, the company recently rebranded and will relabel the vehicles under Bollinger Motors beginning in the 2026 model year. The product lineup also includes the Bollinger B4 Class 4 truck,…

WednesdayAug 06, 2025 9:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal…

WednesdayAug 06, 2025 9:20 am

QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Report Q2 2025 Financial Results on August 14

NextPlat (NASDAQ: NXPL, NXPLW) a global provider of healthcare and technology solutions, will release its financial results for the quarter ended June 30, 2025, before market open on August 14. A conference call hosted by Interim CEO David Phipps and CFO Cecile Munnik will follow at 8:30 a.m. EDT to review the results and discuss recent developments. To view the full press release, visit: https://ibn.fm/BOgDL About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses…

WednesdayAug 06, 2025 9:10 am

QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Applauds FAA Proposal to Normalize BVLOS Drone Operations

Safe Pro Group (NASDAQ: SPAI), a leader in AI-powered defense and security solutions, welcomed the FAA’s proposed rules to streamline Beyond Visual Line of Sight (BVLOS) drone operations. The Company expects the move will accelerate adoption of its computer vision and object detection technologies across government, public, and commercial sectors. Safe Pro’s Airborne Response unit is a top provider of drone-based infrastructure inspections in Florida, and its AI technology has been field-tested in Ukraine to detect landmines and threats with high-speed accuracy. The Company is integrating these capabilities to expand services in public safety, disaster response, and environmental protection. To…

Site Search

Company Search